Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    general medicine

    Glucose-6-phosphate dehydrogenase deficiency

    Also known as: G6PD deficiency, Glucose-6-phosphate dehydrogenase enzyme deficiency, G6PD-associated haemolytic susceptibility

    Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited enzymopathy of the erythrocytes predisposing them to oxidative haemolysis. This premature destruction of red blood cells typically occurs secondary to triggers including specific pharmacotherapy, infections, or ingestion of fava beans. While patients may remain asymptomatic between episodes, neonatal jaundice and acute anaemia necessitate urgent clinical evaluation. Management prioritises trigger avoidance, rigorous medication screening, and prompt intervention for complications. TCM may be considered only for persistent, medically assessed symptoms such as fatigue or sleep disturbance; it cannot restore enzymatic function or prevent haemolysis. Current evidence does not establish the efficacy or safety of acupuncture or herbal medicine for G6PD deficiency. The patterns described constitute traditional symptomatic frameworks rather than discrete pathological subtypes; formulas are provided as educational references, not recommendations to prescribe.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Ensure G6PD deficiency is documented in all medical records and maintain accessible medication-alert information at all times.
    • •Consult a pharmacist or clinician to verify the suitability of every new medication, supplement, or herbal product; do not discontinue prescribed pharmacotherapy independently.
    • •Avoid fava beans and identified individual triggers; consult the medical team regarding household chemical exposures, such as naphthalene (mothballs).
    • •Maintain regular nutritional intake, adequate sleep hygiene, and moderate physical activity; seek early medical intervention for infections and adhere to recommended vaccination schedules and clinical follow-up.

    Cautions & Contraindications

    See sources
    • •Defer needling with active bleeding, suspected profound thrombocytopenia or acute medical instability. Record 1 supports vigilance for severe treatment-associated platelet decline, not a universal platelet abnormality in G6PD deficiency; needling deferral is a precautionary application.[]
    • •Do not infer that a natural product is safe in G6PD deficiency from computational toxicity predictions or animal studies. Record 3 concerns rheumatoid arthritis and explicitly leaves safety and interactions unresolved; it does not validate any listed formula.[]
    • •Do not extrapolate the paediatric influenza formulation's reported safety to G6PD deficiency, other formulas, neonates or pregnancy. Record 4 supplies no G6PD-specific safety analysis and does not justify replacing indicated antiviral or other medical treatment.[]

    When to reassess or seek care again

    See sources

    For a medically stable adult choosing adjunctive symptom care, document baseline fatigue and sleep scores on 0–10 scales and activity tolerance; review within 2–4 weeks. Stop or reconsider care without meaningful improvement. New jaundice, dark urine, bleeding, breathlessness or rapid deterioration requires immediate medical escalation rather than waiting for review. Blood count, haemolysis markers and renal testing are directed by the medical team, not by TCM pattern findings.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Case reports in cardiology · 2026
    2. Medicine · 2026
    3. Life (Basel, Switzerland) · 2026
    4. Frontiers in pharmacology · 2025

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.